{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:21:10Z","timestamp":1789014070164,"version":"build-2803163510"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T00:00:00Z","timestamp":1669507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T00:00:00Z","timestamp":1669507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1038\/s41375-022-01766-z","type":"journal-article","created":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T11:28:15Z","timestamp":1669548495000},"page":"240-243","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azacitidine-based therapy"],"prefix":"10.1038","volume":"37","author":[{"given":"Amer M.","family":"Zeidan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3352-0902","authenticated-orcid":false,"given":"Jan Philipp","family":"Bewersdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Hasle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8542-2944","authenticated-orcid":false,"given":"Rory M.","family":"Shallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7953-7625","authenticated-orcid":false,"given":"Daniel Lopes","family":"de Menezes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelonidta","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Boss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2737-9810","authenticated-orcid":false,"given":"Stephanie","family":"Halene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Haferlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,27]]},"reference":[{"key":"1766_CR1","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel. Blood. 2022;140:1345\u201377.","DOI":"10.1182\/blood.2022016867"},{"key":"1766_CR2","doi-asserted-by":"crossref","unstructured":"Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020;26:1549\u201356.","DOI":"10.1038\/s41591-020-1008-z"},{"key":"1766_CR3","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209\u201321.","journal-title":"N Engl J Med"},{"key":"1766_CR4","doi-asserted-by":"publisher","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","volume":"1","author":"E Bernard","year":"2022","unstructured":"Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Ossa JEA, Nannya Y, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid. 2022;1:EVIDoa2200008.","journal-title":"NEJM Evid"},{"key":"1766_CR5","doi-asserted-by":"crossref","unstructured":"Weinberg OK, Siddon AJ, Madanat Y, Gagan J, Arber DA, Dal Cin P, et al. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS\/AML. Blood Adv. 2022;6:2847\u201353.","DOI":"10.1182\/bloodadvances.2021006239"},{"key":"1766_CR6","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1182\/blood.2021014472","volume":"139","author":"T Grob","year":"2022","unstructured":"Grob T, Al Hinai ASA, Sanders MA, Kavelaars FG, Rijken M, Gradowska PL, et al. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2022;139:2347\u201354.","journal-title":"Blood"},{"key":"1766_CR7","doi-asserted-by":"crossref","unstructured":"Tashakori M, Kadia TM, Loghavi S, Daver NG, Kanagal-Shamanna R, Pierce SR, et al. TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. Blood. 2022;140:58\u201372.","DOI":"10.1182\/blood.2021013983"},{"key":"1766_CR8","doi-asserted-by":"crossref","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data. Blood. 2022;140:1200\u201328.","DOI":"10.1182\/blood.2022015850"},{"key":"1766_CR9","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"1766_CR10","doi-asserted-by":"crossref","unstructured":"Shallis RM, Bewersdorf JP, Stahl MF, Halene S, Zeidan AM. Are we moving the needle for patients with TP53-mutated acute myeloid leukemia? Cancers (Basel). 2022;14:2434.","DOI":"10.3390\/cancers14102434"},{"key":"1766_CR11","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","volume":"26","author":"E Bernard","year":"2020","unstructured":"Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020;26:1549\u201356.","journal-title":"Nat Med"},{"key":"1766_CR12","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1182\/bloodadvances.2021005487","volume":"6","author":"AM Zeidan","year":"2022","unstructured":"Zeidan AM, Boss I, Beach CL, Copeland WB, Thompson E, Fox BA, et al. A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes. Blood Adv. 2022;6:2207\u201318.","journal-title":"Blood Adv"},{"key":"1766_CR13","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1182\/bloodadvances.2021006138","volume":"6","author":"AM Zeidan","year":"2022","unstructured":"Zeidan AM, Boss I, Beach CL, Copeland WB, Thompson E, Fox BA, et al. A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML. Blood Adv. 2022;6:2219\u201329.","journal-title":"Blood Adv"},{"key":"1766_CR14","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642\u20139.","journal-title":"J Clin Oncol"},{"key":"1766_CR15","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419\u201325.","journal-title":"Blood"},{"key":"1766_CR16","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329.","journal-title":"N Engl J Med"},{"key":"1766_CR17","doi-asserted-by":"publisher","first-page":"106","DOI":"10.6004\/jnccn.2022.0009","volume":"20","author":"PL Greenberg","year":"2022","unstructured":"Greenberg PL, Stone RM, Al-Kali A, Bennett JM, Borate U, Brunner AM, et al. NCCN Guidelines\u00ae insights: myelodysplastic syndromes, version 3.2022. J Natl Compr Canc Netw. 2022;20:106\u201317.","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01766-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01766-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01766-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T11:12:14Z","timestamp":1674817934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01766-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,27]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["1766"],"URL":"https:\/\/doi.org\/10.1038\/s41375-022-01766-z","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,27]]},"assertion":[{"value":"15 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AMZ received research funding (institutional) from Celgene\/BMS, Abbvie, Astex, Pfizer, Medimmune\/AstraZeneca, Boehringer-Ingelheim, Cardiff oncology, Incyte, Takeda, Novartis, Aprea, and ADC Therapeutics. AMZ participated in advisory boards, and\/or had a consultancy with and received honoraria from AbbVie, Otsuka, Pfizer, Celgene\/BMS, Jazz, Incyte, Agios, Boehringer-Ingelheim, Novartis, Acceleron, Astellas, Daiichi Sankyo, Cardinal Health, Taiho, Seattle Genetics, BeyondSpring, Cardiff Oncology, Takeda, Ionis, Amgen, Janssen, Epizyme, Syndax, Gilead, Kura, Chiesi, ALX Oncology, BioCryst, Notable, Orum, and Tyme. AMZ served on clinical trial committees for Novartis, Abbvie, Gilead, BioCryst, Abbvie, ALX Oncology, Geron and Celgene\/BMS. RMS participated in advisory boards, and\/or had a consultancy with and received honoraria from Bristol Myers Squibb and Gilead Sciences, Inc; divested equity interest in Curis Oncology. IB, ET, BAF, VEH, and SR are employees of Celgene, a Bristol Myers Squibb company, and may be shareholders. SH has received research funding received honoraria from FORMA Therapeutics. TH is the owner of Munich Leukemia Laboratory. All other authors have no relevant conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}